Who is eligible for clinical trial NCT05952557?

Participants must meet protocol criteria for Breast Cancer, Early Breast Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05952557 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-07

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (NCT05952557)

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Who can join: Review the eligibility criteria below.

Location: Research Site — Dothan, Alabama

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (661 Sites)

Showing the first 25 of 661 sites.

Research Site — Dothan, Alabama
Research Site — Phoenix, Arizona
Research Site — Tucson, Arizona
Research Site — Fayetteville, Arkansas
Research Site — Duarte, California
Research Site — Fountain Valley, California
Research Site — Irvine, California
Research Site — La Jolla, California
Research Site — Los Angeles, California
Research Site — Walnut Creek, California
Research Site — West Hollywood, California
Research Site — Aurora, Colorado
Research Site — Littleton, Colorado
Research Site — Littleton, Colorado
Research Site — New Haven, Connecticut
Research Site — Newark, Delaware
Research Site — Clearwater, Florida
Research Site — Fort Myers, Florida
Research Site — Gainesville, Florida
Research Site — Jacksonville, Florida
Research Site — Pembroke Pines, Florida
Research Site — Plantation, Florida
Research Site — Plantation, Florida
Research Site — St. Petersburg, Florida
Research Site — St. Petersburg, Florida

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer, Early Breast Cancer

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Birmingham, Alabama

Explore by condition: All Breast Cancer, Early Breast Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗